Basran Raveen K, Reiss Ulrike M, Luo Hong-Yuan, Ware Russell E, Chui David H K
Hemoglobin Diagnostic Reference Laboratory, Boston Medical Center, Boston, Massachusetts, USA.
Pediatr Blood Cancer. 2008 Feb;50(2):363-6. doi: 10.1002/pbc.20916.
An 8-year-old African-American boy had a clinical history consistent with mild beta-thalassemia intermedia with moderate anemia, microcytosis, reticulocytosis, and splenomegaly. He was asymptomatic and did not require transfusion. At age 4 years, hemoglobin (Hb) electrophoresis showed Hb A = 37.8%, Hb A(2) = 5.0%, and Hb F = 56.1%. At age 8 years, he was diagnosed to be a compound heterozygote for two beta-globin gene promoter mutations, the relatively common nucleotide (nt) -88 C --> T mutation from the cap site, and a novel two-nucleotide (AA) deletion between nt -29 and -26 within the TATA box of the beta-globin gene. His mother and 14-year-old brother were simple heterozygotes for this novel (AA) deletion. Both heterozygotes had normal Hb level, borderline microcytosis, and elevated Hb A(2).
一名8岁非裔美国男孩的临床病史符合轻度中间型β地中海贫血,伴有中度贫血、小红细胞症、网织红细胞增多和脾肿大。他没有症状,也不需要输血。4岁时,血红蛋白(Hb)电泳显示Hb A = 37.8%,Hb A2 = 5.0%,Hb F = 56.1%。8岁时,他被诊断为β珠蛋白基因启动子两个突变的复合杂合子,一个是帽位点相对常见的核苷酸(nt)-88 C→T突变,另一个是β珠蛋白基因TATA盒内nt -29和-26之间的新型两核苷酸(AA)缺失。他的母亲和14岁的哥哥是这种新型(AA)缺失的单纯杂合子。两名杂合子的Hb水平正常,有临界小红细胞症,且Hb A2升高。